Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04405375

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Extranodal NK/T-cell Lymphoma, Nasal Type Clinical Trial

Official title:
Gemcitabine, Pegaspargase, Etoposide, and Dexamethasone (GPED) for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).

Clinical Trial Description

Pegaspargase is the cornor stone for the treatment of ENKTCL, and gemcitabine has been shown to be active in ENKTCL. For several patients with relapsed/refractory or advance ENKTCL, hemophagocytic sysdrome (HPS) occurs, and the prognosis is very poor. Studies have found that etoposide and dexamethasone may be effective in controlling HPS. Thus, this study aims to evaluate the role of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of relapsed/refractory or advance ENKTCL, wishing to improve the prognosis for these patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04405375
Study type Interventional
Source Beijing Tongren Hospital
Contact
Status Recruiting
Phase Phase 2
Start date March 21, 2020
Completion date April 30, 2023
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04509466 - Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL Phase 1/Phase 2
Not yet recruiting NCT04676789 - Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL Phase 2
Active, not recruiting NCT01991158 - GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma Phase 2
Active, not recruiting NCT03363555 - SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma Phase 2
Recruiting NCT02742727 - CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Phase 1/Phase 2
Active, not recruiting NCT02631239 - MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma Phase 3
Recruiting NCT01667302 - Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma Phase 2
Terminated NCT01667289 - Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma Phase 2
Not yet recruiting NCT04338282 - Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma Phase 2
Active, not recruiting NCT04414163 - A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type Phase 2
Recruiting NCT05978141 - A Registry for People With T-cell Lymphoma
Completed NCT02386813 - International Extranodal NK/T-cell Lymphoma Project N/A
Recruiting NCT01921790 - Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma Phase 2
Completed NCT03493451 - Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Phase 2